A Review on the Safety of Using JAK Inhibitors in Dermatology: Clinical and Laboratory Monitoring
Abstract Janus kinase (JAK) inhibitors are disease-modifying agents with efficacy in treating a spectrum of burdensome dermatologic conditions. The US Food and Drug Administration (FDA) recently placed a black box warning on this class of medications due to safety concerns based on data from studies...
| 出版年: | Dermatology and Therapy |
|---|---|
| 主要な著者: | , , , |
| フォーマット: | 論文 |
| 言語: | 英語 |
| 出版事項: |
Adis, Springer Healthcare
2023-02-01
|
| 主題: | |
| オンライン･アクセス: | https://doi.org/10.1007/s13555-023-00892-5 |